Program
Interferon beta-1a
Also written as “Rebif®”, “RNF” and “Rebif”.
Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · COVID-19 · Colitis, Ulcerative · Pneumonia, Viral, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 230 open or running | phase 4since Sep 13, 2005 | Dec 15, 2004 | none ahead |
| Merck KGaA, Darmstadt, Germany | 210 open or running | phase 4since Feb 23, 2004 | Feb 23, 2004 | none ahead |
| Faron Pharmaceuticals | 30 open or running | phase 3since Nov 24, 2015 | Nov 24, 2015 | none ahead |
| Biocad | 20 open or running | phase 3since May 29, 2015 | Jan 10, 2013 | none ahead |
| Cinnagen | 20 open or running | phase 3since Jan 17, 2022 | Jul 14, 2018 | none ahead |
| Azidus Brasil | 10 open or running | phase 1since Nov 13, 2009 | Nov 13, 2009 | none ahead |
| Trio Medicines | 10 open or running | phase 1since May 20, 2013 | May 20, 2013 | none ahead |
Also a collaborator on its studies: toray-industries-inc, Pfizer, gesellschaft-fu-r-therapieforschung-mbh, merck-serono-s-p-a-italy, merck-serono-s-a-s-france, emd-serono-canada-inc, elan-pharmaceuticals, merck-pte-ltd-singapore and merck-serono-international-sa.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 39 studies since Feb 23, 2004.
- Jan 10, 2013Biocad's first study: phase 1 study in HealthyNew to BiocadBiocad · NCT01766024 · 32 enrolled · Russian Federation
- Feb 12, 2013Phase 4 study in Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT01791244 · 93 enrolled · Germany, Sweden
- May 20, 2013Trio Medicines's first study: phase 1 study in Multiple SclerosisNew to Trio MedicinesTrio Medicines · NCT01863069 · 77 enrolled · United Kingdom
- Feb 13, 2014Phase 4 study in Multiple Sclerosis, Relapsing-RemittingMerck KGaA, Darmstadt, Germany · NCT02064816 · 200 enrolled · Germany
- Apr 15, 2014Phase 4 study in Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT02117050 · 1 enrolled · United States
- Sep 29, 2014Phase 4 study in Relapsing Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT02254304 · 106 enrolled · Germany
- Oct 17, 2014Phase 1 study in Multiple SclerosisBiogen · NCT02269930 · 30 enrolled · United States
- May 29, 2015Phase 3 study in Multiple SclerosisBiocad · NCT02727907 · 163 enrolled · Russian Federation
- Nov 24, 2015Faron Pharmaceuticals's first study: phase 3 study in Respiratory Distress SyndromeNew to Faron PharmaceuticalsFaron Pharmaceuticals · NCT02622724 · 301 enrolled · Belgium, Czechia, Finland and more
- Jan 26, 2017Phase 4 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT03177083 · 80 enrolled · Portugal
- Mar 3, 2017Phase 2 study in Multiple Organ FailureFaron Pharmaceuticals · NCT03119701 · 40 enrolled · Estonia, Finland, Lithuania
- Jul 14, 2018Cinnagen's first study: phase 1 study in BioequivalenceNew to CinnagenCinnagen · NCT03614715 · 40 enrolled · Finland
- Apr 22, 2021Phase 2 study in COVID-19Faron Pharmaceuticals · NCT04860518 · 7 enrolled · United States
- Jan 17, 2022Phase 3 study in Multiple Sclerosis, Relapsing-RemittingCinnagen · NCT05242133 · 168 enrolled · Iran, Islamic Republic of
TargetBeta
“A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities”NCIt, by rule
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule
Studies
All 53 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05242133Multiple Sclerosis, Relapsing-Remitting · Iran, Islamic Republic of | 3 | Completed | Cinnagen | Apr 27, 2022 | 168 |
| NCT04860518COVID-19 · United States | 2 | Terminated | Faron Pharmaceuticals | Apr 4, 2022 | 7 |
| NCT03614715Bioequivalence · Finland | 1 | Completed | Cinnagen | Feb 12, 2019 | 40 |
| NCT03119701Multiple Organ Failure · Estonia, Finland, Lithuania | 2 | Terminated | Faron Pharmaceuticals | Sep 23, 2019 | 40 |
| NCT03177083Multiple Sclerosis, Relapsing-Remitting · Portugal | 4 | Completed | Biogen | Oct 26, 2020 | 80 |
| NCT02622724Respiratory Distress Syndrome · Belgium, Czechia, Finland and more | 3 | Terminated | Faron Pharmaceuticals | May 17, 2018 | 301 |
| NCT02727907Multiple Sclerosis · Russian Federation | 3 | Completed | Biocad | Nov 21, 2016 | 163 |
| NCT02269930Multiple Sclerosis · United States | 1 | Completed | Biogen | Dec 2014 | 30 |
| NCT02254304Relapsing Multiple Sclerosis · Germany | 4 | Completed | Merck KGaA, Darmstadt, Germany | Aug 20, 2016 | 106 |
| NCT02117050Multiple Sclerosis · United States | 4 | Terminated | Merck KGaA, Darmstadt, Germany | Apr 2015 | 1 |
| NCT02064816Multiple Sclerosis, Relapsing-Remitting · Germany | 4 | Completed | Merck KGaA, Darmstadt, Germany | Apr 30, 2016 | 200 |
| NCT01863069Multiple Sclerosis · United Kingdom | 1 | Completed | Trio Medicines | Oct 2001 | 77 |
| NCT01791244Multiple Sclerosis · Germany, Sweden | 4 | Completed | Merck KGaA, Darmstadt, Germany | Feb 29, 2016 | 93 |
| NCT01766024Healthy · Russian Federation | 1 | Completed | Biocad | Jun 2013 | 32 |
| NCT01500408Multiple Sclerosis · United States | 1 | Completed | Biogen | Apr 2012 | 110 |
| NCT01416207Healthy · China | 1 | Completed | Biogen | Oct 2011 | 24 |
| NCT01285401Multiple Sclerosis, Relapsing-Remitting · Austria, Denmark, Estonia and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Apr 2015 | 260 |
| NCT01201343Multiple Sclerosis, Relapsing-Remitting | 4 | Completed | Merck KGaA, Darmstadt, Germany | Jul 2010 | 79 |
| NCT01181115Multiple Sclerosis · China | 3 | Completed | Biogen | Oct 2011 | 60 |
| NCT01142466Multiple Sclerosis, Relapsing-Remitting | 4 | Completed | Merck KGaA, Darmstadt, Germany | Dec 2009 | 30 |
| NCT01119677Healthy Volunteers · United States | 1 | Completed | Biogen | Oct 23, 2010 | 120 |
| NCT01085318Multiple Sclerosis · United States | 4 | Completed | Merck KGaA, Darmstadt, Germany | Feb 29, 2012 | 38 |
| NCT01075763Alzheimer Disease · Italy | 2 | Completed | Merck KGaA, Darmstadt, Germany | May 2008 | 42 |
| NCT01071083Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Spain | 2 | Completed | Biogen | Nov 2011 | 175 |
| NCT01074593Healthy · Brazil | 1 | Completed | Azidus Brasil | Mar 2011 | 20 |
| NCT00915577Multiple Sclerosis | 3 | Completed | Biogen | Apr 2006 | 74 |
| NCT00915460Multiple Sclerosis | 4 | Completed | Biogen | Jun 2003 | 408 |
| NCT00913666Multiple Sclerosis | 4 | Completed | Biogen | 121 | |
| NCT00913250Multiple Sclerosis | 1 | Completed | Biogen | 96 | |
| NCT00912860Multiple Sclerosis | 2 | Completed | Biogen | Dec 2004 | 155 |
| NCT00828204Multiple Sclerosis · United States | 3 | Completed | Biogen | Jul 2010 | 95 |
| NCT00813709Multiple Sclerosis · Argentina, Austria, Belgium and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2011 | 402 |
| NCT00784836Multiple Sclerosis · United States | 3 | Terminated | Biogen | Feb 2009 | 3 |
| NCT00771043Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | Biogen | Aug 1, 2009 | 0 |
| NCT00725985Multiple Sclerosis · United States, Argentina, Austria and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Jul 31, 2011 | 617 |
| NCT00616434Active Ulcerative Colitis · United States, Canada, Czech Republic and more | 2 | Completed | Biogen | Mar 2010 | 123 |
| NCT00574041Multiple Sclerosis, Relapsing-Remitting · Australia | 4 | Terminated | Biogen | Feb 2008 | 19 |
| NCT00534261Multiple Sclerosis, Relapsing-Remitting · Belgium, Luxembourg, United Kingdom | 4 | Completed | Biogen | 284 | |
| NCT00493116Multiple Sclerosis, Relapsing-Remitting · Australia, New Zealand | 4 | Completed | Biogen | Dec 2009 | 20 |
| NCT00493077Multiple Sclerosis · Sweden | 4 | Completed | Biogen | May 2006 | 3 |
| NCT00492466Multiple Sclerosis, Relapsing-Remitting · Finland | 4 | Completed | Biogen | Aug 2006 | 14 |
| NCT00441103Multiple Sclerosis, Relapsing-Remitting | 3 | Completed | Merck KGaA, Darmstadt, Germany | Nov 2008 | 180 |
| NCT00404352Multiple Sclerosis · Argentina, Australia, Austria and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2010 | 517 |
| NCT00367484Multiple Sclerosis, Relapsing-Remitting | 4 | Completed | Merck KGaA, Darmstadt, Germany | Jan 2006 | 460 |
| NCT00304252Crohn Disease · Germany, Italy, Sweden and more | 2 | Terminated | Merck KGaA, Darmstadt, Germany | 192 | |
| NCT00303381Colitis, Ulcerative · Germany, Israel, Netherlands and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Jan 2003 | 194 |
| NCT00292266Multiple Sclerosis, Relapsing-Remitting | 3 | Completed | Merck KGaA, Darmstadt, Germany | Jun 2002 | 677 |
| NCT00287079Clinically Isolated Syndrome · Canada | 3 | Completed | Merck KGaA, Darmstadt, Germany | Nov 2008 | 35 |
| NCT00249860Hepatitis C | 3 | Completed | Merck KGaA, Darmstadt, Germany | Aug 2005 | 257 |
| NCT00168766Multiple Sclerosis, Relapsing-Remitting · Belgium, Denmark, Finland and more | 4 | Completed | Biogen | Nov 2008 | 345 |
| NCT00101959Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | Merck KGaA, Darmstadt, Germany | 0 | |
| NCT00099489Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Canada and more | 2 | Completed | Biogen | Feb 2006 | 67 |
| NCT00078338Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Austria and more | 4 | Completed | Merck KGaA, Darmstadt, Germany | Nov 28, 2006 | 764 |
How it is read
Names in the registry
- “Interferon beta-1a”, 11 entries
- “Rebif®”, 7 entries
- “RNF”, 5 entries
- “Rebif”, 4 entries
- “SNG001”, 3 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 21 studies
- Multiple Sclerosis, Relapsing-Remitting, 18 studies
- COVID-19, 3 studies
- Colitis, Ulcerative, 2 studies
- Pneumonia, Viral, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.